Sage Journals: Discover world-class research

Abstract

Background:

Alemtuzumab, approved for multiple sclerosis (MS), can cause secondary autoimmune adverse events including thyroid disorders, immune thrombocytopenia (ITP), and glomerular nephropathies. Non-ITP autoimmune cytopenias are rarely reported.

Objective:

To report a case of autoimmune hemolytic anemia (AIHA) and nephropathy in a MS patient treated with alemtuzumab.

Case report:

A 34-year-old man with MS developed albuminuria and AIHA after the first and only alemtuzumab treatment, with positive Coombs’ direct and indirect tests and IgG autoantibodies. Both AIHA and nephropathy resolved 1 month after treatment with steroids and intravenous immunoglobulins.

Conclusion:

Our report adds to literature on AIHA and nephropathy after alemtuzumab treatment and suggests to add Coombs’ tests to the screening panel required for alemtuzumab treatment.

Keywords

Multiple sclerosis alemtuzumab autoimmune hemolytic anemia glomerular nephropathy albuminuria

Get full access to this article

View all access options for this article.

References

Havrdova

Horakova

Kovarova

Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8(1): 31–45.

Jones

Coles

AJ.

Mode of action and clinical studies with alemtuzumab. Exp Neurol 2014; 262 (Pt A): 37–43.

Cohen

JA1

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1819–1828.

Coles

AJ1

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1829–1839.

Saeedi

Forughipour

Sasannezhad

et al . Interferon-beta-1b induced autoimmune hemolytic anemia in a patient with MS: A case report. Iran Red Crescent Med J 2011; 13(3): 210–212.

Alanoglu

Kilbas

Arslan

et al . Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis. Mult Scler 2007; 13(5): 683–685.

Lysandropoulos

Benghiat

Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Mult Scler 2013; 19(11): 1551–1552.

Ozturk

Basoglu

Yilmaz

et al . Interferon β associated nephropathy in a multiple sclerosis patient: A case and review. Mult Scler Relat Disord 2016; 9: 50–53.

Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis

Abstract

Background:

Objective:

Case report:

Conclusion:

Keywords

Get full access to this article

References